Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PepGNP-ChikV Vaccine in Healthy Adults
NCT07394426Phase 1Not yet recruiting
- Sponsor
- Gylden Pharma
- Start
- Aug 2026
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Peptide-based Cancer Vaccines
01
Overview
Phase 1, randomised, single-blind trial of PepGNP-ChikV in Chikungunya (CHIKV) (2 arms), sponsored by Gylden Pharma. Primary endpoints: Safety of PepGNP-ChikV candidate vaccine, Reactogenicity of PepGNP-ChikV candidate vaccine and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
PepGNP-ChikV
03
Conditions
Chikungunya (CHIKV)
Beyond the preview
Go deeper on NCT07394426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07394426.